|
1
|
Montalbano J, Lui K, Sheikh MS and Huang
Y: Identification and characterization of RBEL1 subfamily of
GTPases in the Ras superfamily involved in cell growth regulation.
J Biol Chem. 284:18129–18142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lui K, An J, Montalbano J, Shi J, Corcoran
C, He Q, Sun H, Sheikh MS and Huang Y: Negative regulation of p53
by Ras superfamily protein RBEL1A. J Cell Sci. 126:2436–2445. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Montalbano J, Jin W, Sheikh MS and Huang
Y: RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras
superfamily GTP-binding protein and is overexpressed in breast
cancer. J Biol Chem. 282:37640–37649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levine AJ, Hu W and Feng Z: The P53
pathway: What questions remain to be explored? Cell Death Differ.
13:1027–1036. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang L, Sheikh MS and Huang Y: Decision
making by p53: Life versus death. Mol Cell Pharmacol. 2:69–77.
2010.PubMed/NCBI
|
|
6
|
Duffy MJ, Synnott NC, McGowan PM, Crown J,
O'Connor D and Gallagher WM: p53 as a target for the treatment of
cancer. Cancer Treat Rev. 40:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ozaki T and Nakagawara A: p53: The
attractive tumor suppressor in the cancer research field. J Biomed
Biotechnol. 2011:6039252011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Higashimoto Y, Asanomi Y, Takakusagi S,
Lewis MS, Uosaki K, Durell SR, Anderson CW, Appella E and Sakaguchi
K: Unfolding, aggregation, and amyloid formation by the
tetramerization domain from mutant p53 associated with lung cancer.
Biochemistry. 45:1608–1619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Dieck J, Fernandez-Fernandez MR,
Veprintsev DB and Fersht AR: Modulation of the oligomerization
state of p53 by differential binding of proteins of the S100 family
to p53 monomers and tetramers. J Biol Chem. 284:13804–13811. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin J, Yang Q, Yan Z, Markowitz J, Wilder
PT, Carrier F and Weber DJ: Inhibiting S100B restores p53 levels in
primary malignant melanoma cancer cells. J Biol Chem.
279:34071–34077. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Foo RS, Nam YJ, Ostreicher MJ, Metzl MD,
Whelan RS, Peng CF, Ashton AW, Fu W, Mani K, Chin SF, et al:
Regulation of p53 tetramerization and nuclear export by ARC. Proc
Natl Acad Sci USA. 104:20826–20831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lui K, Sheikh MS and Huang Y: Regulation
of p53 oligomerization by Ras superfamily protein RBEL1A. Genes
Cancer. 6:307–316. 2015.PubMed/NCBI
|
|
13
|
Boulikas T and Vougiouka M: Cisplatin and
platinum drugs at the molecular level. (Review). Oncol Rep.
10:1663–1682. 2003.PubMed/NCBI
|
|
14
|
Stavridi ES, Chehab NH, Caruso LC and
Halazonetis TD: Change in oliogmerization specificity of the p53
tetramerization domain by hydrophobic amino acid substitutions.
Protein Sci. 8:1773–1779. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandez-Fernandez MR, Veprintsev DB and
Fersht AR: Proteins of the S100 family regulate the oligomerization
of p53 tumor suppressor. Proc Natl Acad Sci USA. 102:4735–4740.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tallarida RJ and Murray RB: Manual of
pharmacologic calculations with computer programs. Springer
Publisher; pp. 100–104. 1986
|
|
18
|
Sekine H, Chen N, Sato K, Saiki Y, Yoshino
Y, Umetsu Y, Jin G, Nagase H, Gu Z, Fukushige S, Sunamura M and
Horii A: S100A4, frequently overexpressed in various human cancers,
accelerates cell motility in pancreatic cells. Biochem Biophys Res
Commun. 429:214–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maletzki C, Bodammer P, Breitrück A and
Kerkhoff C: S100 proteins as diagnostic and prognostic markers in
colorectal and hepatocellular carcinoma. Hepat Mon. 12(10 HCC):
e72402012.PubMed/NCBI
|
|
20
|
Mercier I, Vuolo M, Jasmin JF, Medina CM,
Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP
and Kitsis RN: ARC (apoptosis repressor with caspase recruitment
domain) is a novel marker of human colon cancer. Cell Cycle.
7:1640–1647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53. Hum
Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelavkar UP and Badr KF: Effects of mutant
p53 expression on human 15-lipoxygenase-promoter activity and
murine 12/15-lipoxygenase gene expression: Evidence that
15-lipoxygenase is a mutator gene. Proc Natl Acad Sci USA.
96:4378–4383. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reddy N, Everhart A, Eling T and Glasgow
W: Characterization of a 15-lipoxygenase in human breast carcinoma
BT-20 cells: Stimulation of 13-HODE formation by TGF alpha/EGF.
Biochem Biophys Res Commun. 231:111–116. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gallagher EJ and LeRoith D: Minireview:
IGF, insulin, and cancer. Endocrinology. 152:2546–2551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
